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The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains is a
serious challenge for HIV-1 vaccine design. We have generated a synthetic group M consensus env gene (CON6)
for induction of cross-subtype immune responses and report here a comparative study of T-cell responses to
this and natural strain env immunogens in a murine model. Three different strains of mice were immunized
with CON6 as well as subtype A, B, or C env immunogens, using a DNA prime-recombinant vaccinia virus boost
strategy. T-cell epitopes were mapped by gamma interferon enzyme-linked immunospot analysis using five
overlapping Env peptide sets from heterologous subtype A, B, and C viruses. The CON6-derived vaccine was
immunogenic and induced a greater number of T-cell epitope responses than any single wild-type subtype A,
B, and C env immunogen and similar T-cell responses to a polyvalent vaccine. The responses were comparable
to within-clade responses but significantly more than between-clade responses. The magnitude of the T-cell
responses induced by CON6 (measured by individual epitope peptides) was also greater than the magnitude
of responses induced by individual wild-type env immunogens. Though the limited major histocompatibility
complex repertoire in inbred mice does not necessarily predict responses in nonhuman primates and humans,
these results suggest that synthetic centralized env immunogens represent a promising approach for HIV-1
vaccine design that merits further characterization.
subtype responses have remained suboptimal, highly variable,
and epitope specific (12, 13, 20, 22, 34). To maximize the
genetic similarity between the candidate vaccine and contemporary HIV-1 strains, to simplify immunogen production, and
to provide a baseline from which to build an optimized vaccine,
we and others have proposed to use centralized HIV-1 gene
sequences (consensus, ancestor, and center of the tree) for
vaccine development (10, 11, 14–16, 24, 30, 31).
Because of the star-like phylogeny of HIV-1, a “central
sequence” will reduce the amino acid divergence between immunogens and field virus strains (14); however, the three kinds
of centralized sequences can differ from each other by 1% to
5%, and their precise sequence depends upon the input data
set of natural strains used to generate them. Comparing experimentally defined cytotoxic T-lymphocyte (CTL) epitopes,
we have found that consensus and ancestral sequences preserve many known HIV-1 CTL epitopes from different viral
strains (14, 16, 39). These observations would predict that
centralized HIV-1 genes induce more broadly cross-reactive
T-cell responses than WT genes.
We previously generated a group M consensus env gene
(CON6) based on the sequences available in the Los Alamos
HIV Sequence Database in 1999. CON6 Env-containing pseudovirions are infectious for CD4/CCR5-bearing target cells, and

The high level of genetic variation among human immunodeficiency virus type 1 (HIV-1) isolates poses a major obstacle
for HIV-1 vaccine development. The HIV-1 “main” (M) group
viruses are primarily responsible for the AIDS pandemic and
are further classified into nine genetically distinct subtypes (A
to D, F to H, J, and K) (26). With protein sequence differences
between Env proteins from various subtypes as high as 35%,
wild-type (WT) HIV-1 genes from any one subtype may not
induce immune responses that will provide consistent crossreactive protection against other subtypes. Countries and even
cities often have multiple subtypes cocirculating (26, 38).
Therefore, a vaccine based on only one strain or subtype is
unlikely to prevent or control HIV-1 infection in most parts of
the world.
T-cell responses play an important role in the control of
viremia in natural infection and vaccinated animals (3, 4, 19,
33, 36). Several candidate vaccines have been shown to induce
T-cell responses against HIV-1, but to date, levels of cross* Corresponding author. Mailing address: Duke Human Vaccine
Institute, Duke University Medical Center; 112 RPIII, Research Drive,
Box 3347, DUMC, Durham, NC 27710. Phone: (919) 668-6433. Fax:
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CON6 Env protein trimers induce neutralizing antibodies
against select HIV-1 primary isolates (15). Here, we report a
comparative study of T-cell responses induced by env genebased DNA and recombinant vaccinia virus (rVV) vaccines
derived from CON6 and three WT subtype A, B, and C HIV-1
strains, tested alone as well as in a polyvalent combination
in mice.

MATERIALS AND METHODS
Env gp140CF immunogens. To generate DNA and rVV vectors expressing
secreted forms of envelope immunogens, CON6 (group M consensus), JRFL
(subtype B), and 96ZM651 (subtype C) gp140CF plasmids were constructed by
introduction of a stop codon before the membrane-spanning domain (YIKIFI
MIVGGLIGLRIVFAVLSIVN) and deletion of the gp120/gp41 cleavage site
and fusion domain of gp41, as previously described (15). Parts of variable regions
(V1, V2, V4, and V5) in CON6 represent the sequences of a contemporary
subtype C strain (98CN006) as described previously (15). 92RW020 (subtype A)
[pVRC5304 (R5 gp140⌬CFI-Clade-A)] contained an additional deletion between HR1 and HR2 in gp41 (22). All env genes were cloned into a DNA
expression vector, pCMV/R, at XbaI and BamHI sites as DNA immunogens.
The same genes were also cloned into the shuttle plasmid pSC65 at SalI and
KpnI sites to generate rVV as previously described (29). The env gene inserts in
both plasmid and rVV DNA were confirmed by PCR and nucleotide sequence
analysis. Plasmid DNA was prepared using GenElute HP Plasmid Maxiprep kits
as described by the supplier (Sigma, St. Louis, MO). Recombinant vaccinia
viruses were purified from infected 293T cell lysates by centrifugation through a
36% sucrose cushion at 32,900 ⫻ g for 2 h at 4°C. Purified viruses were titrated
on HuTK⫺ 143B cells.
Immunizations. Female BALB/c, C57BL/6, and C3H-NeJ mice (6 to 8 weeks
old) were purchased from Charles River Laboratories (Wilmington, Mass.) and
housed in the Duke University Animal Facility under the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) guidelines
with animal use protocols approved by the Duke University Animal Use and
Care Committee. Five mice per group were immunized intramuscularly (i.m.) in
the quadriceps with gp140CF or gp140⌬CFI and empty vector control DNA (50
g) three times at 3-week intervals. Three weeks after the last DNA immunization, mice were boosted with rVVs and wild-type VV (107 PFU). For the
polyvalent group (a mixture of A_92RW020, B_JRFL, and C_96ZM651), onethird doses of DNA (17 g) or rVV (0.33 ⫻ 107 PFU) were used for each
immunogen. Two weeks after rVV boost, mice were euthanized and spleens were
collected.
ELISpot assay. For the enzyme-linked immunospot (ELISpot) assay, a total of
five overlapping Env peptide sets from subtypes A, B, and C were used for T-cell
epitope mapping. The Envs used for reagent design were from heterologous
viruses relative to the vaccine strains. Subtype A (92UG037) gp140 overlapping
peptides were synthesized through SynPep Corporation (Dublin, CA) and consisted of 168 peptides that were 15 amino acids long with an 11-amino-acid
overlap. Subtype B (MN, SF162P3, and 89.6) and subtype C (Chn19) peptides
were obtained from the NIH AIDS Research and Reference Reagent Program
(Bethesda, MD). The MN and SF162P3 peptide sets consisted of 174 and 182
peptides, respectively. They were 15 amino acids long, with an 11-amino-acid
overlap. The 89.6 and Chn19 peptide sets consisted of 72 peptides that were 20
amino acids long with a 10-amino-acid overlap. Amino acid distances between
the Env immunogen and Env peptide sequences are summarized in Table 1. As
expected, each subtype immunogen was less divergent from peptide sequences
from the same subtype than from peptide sequences from other subtypes. The
distances between CON6 and any subtype peptide sequence were comparable to
within-subtype distances.
Spleens from individual mice were minced and forced through a 70-m nylon
cell strainer (BD Labware, Franklin Lakes, NJ). Single-cell suspensions of
splenocytes were plated in 96-well polyvinylidene difluoride-backed plates (MultiScreen-IP; Millipore, Billerica, MA) coated with 50 l of anti-mouse gamma
interferon (IFN-␥) monoclonal antibody (MAb), AN18 (5 g/ml; Mabtech,
Stockholm, Sweden), overnight at 4°C. The plates were blocked with HEPESbuffered complete RPMI medium at 37°C for 2 h. Equal volumes (50 l) of each
peptide pool and splenocytes (107 cells/ml) were added to the wells in duplicate.
All peptides from 89.6 or Chn19 were used in one pool. Peptides from 92UG037,
MN, and SF162P3 were equally divided into two pools to keep the peptide
numbers similar as for 89.6 and Chn19. The final concentration of each peptide
was 1 g/ml. Plates were incubated overnight (14 to 16 h) at 37°C with 5% CO2.

TABLE 1. Amino acid distances between Env immunogens
and peptides
Immunogen

Peptide

% Distance

A_92RW020

92UG037 (subtype A)
Other subtypes

20.10
24.20

B_JRFL

MN, 89.6 and SF162P3 (subtype B)
Other subtypes

14.50
23.70

C_96ZM651

Chn19 (subtype C)
Other subtypes

18.70
27.00

CON6

Subtypes

18.50

Among subtypes

25.00

After the plates were washed six times with phosphate-buffered saline (PBS), 50
l of 1:1,000-diluted biotinylated anti-mouse IFN-␥ MAb (Mabtech, Stockholm,
Sweden) was added to each well. Plates were incubated at room temperature
(RT) for 2 h and then washed with PBS (three times), and 50 l of streptavidinalkaline phosphatase conjugate (1:1,000 dilution; Mabtech, Stockholm, Sweden)
was added to each well. After incubation (RT for 1 h), the plates were washed
with PBS plus 0.05% Tween 20 (five times). Finally, 100 l of BCIP/NBT (Plus)
(5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium) alkaline phosphatase substrate (Moss, Pasadena, MD) was added to each well. The plates
were incubated at RT for 10 min. After washing with water, plates were air dried.
Spots were counted using an automated ELISpot plate reader (Immunospot
counting system; CTL Analyzers, Cleveland, OH) and expressed as spot-forming
cells (SFC) per 106 splenocytes. Responses were considered as positive if the
number of the spots was fourfold higher than that of the negative control and at
least 50 SFC/106 cells. CD4⫹ and CD8⫹ T-cell depletion and enrichment were
performed using immunomagnetic depletion beads according to the manufacturer’s instructions (DYNAL BIOTECH ASA, Oslo, Norway). ELISpot assays
were performed with depleted CD4⫹ or CD8⫹ T cells to determine whether the
T-cell epitopes were either major histocompatibility complex (MHC) class I or II
restricted.
Statistical analysis. The logistic regression models (2, 8) used in this study to
investigate the breadth of induced responses were constructed using the statistics
package R (www.r-project.org) (32) to fit saturated models and then progressively to eliminate all statistically insignificant interactions: a similar analysis is
detailed in, for example, reference 2. One of the models was overdispersed, so we
applied the methods described by McCullagh and Nelder (28) to model the
overdispersion. In addition, we performed Poisson regressions to model the
magnitude of the responses (in SFC per 106 splenocytes), but as these models did
not fit very well, we will not discuss them below. The poor fit in these Poisson
models is not unexpected: given the considerable variation in immune response
between individual mice, it would be surprising if the immunogen and epitope
types provided sufficient explanatory power to yield an accurate numerical prediction of the strength of the response. To accommodate this strong biological
variation, we have concentrated on more robust statistical procedures. To explore the breadth of the responses, we used the logistic regressions described
above in which each response was treated as a Boolean “yes or no” according to
whether the response exceeded the threshold of detection and we analyzed
contingency tables with Fisher’s exact test. Finally, we used rank-based statistics
when comparing the magnitudes of responses. These included Kruskal-Wallis
tests to compare multiple categories of vaccine groups, coupled with Wilcoxon
rank sum tests for further refinement of relationships between pairs of categories. ELISpot tests were done in duplicate; the single highest score for each
duplicate test performed was used to compare magnitudes of responses between
vaccine groups.

RESULTS
Breadth of cross-subtype T-cell responses induced by CON6.
We determined T-cell responses induced by CON6 and compared these with responses induced by WT Env immunogens
administered via a DNA prime/rVV boost immunization strategy.
Six groups of mice were immunized with A_92RW020 gp140⌬CFI
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FIG. 1. T-cell immune responses induced by CON6 and subtype Env immunogens in BALB/c, C57BL/6, and C3H-NeJ mice. Splenocytes were
isolated from individual immunized mice (5 mice/group) and stimulated in vitro with five overlapping Env peptide pools. Two pools were used for
A_92UG037 (84 peptides in each pool), B_MN (87 peptides in each pool), and SF162P3 (92 peptides in each pool), and one pool was used for
B_89.6 (72 peptides) and Chn19 (72 peptides). INF-␥-producing cells were determined by ELISpot analysis. Total responses for each immunogen
and peptide pool are expressed as SFC per million splenocytes. The values for each column are the mean ⫾ standard error IFN-␥ SFC (n ⫽ 5).

(subtype A), B_JRFL gp140CF (subtype B), C_96ZM651 gp140CF
(subtype C), a polyvalent mixture (A_92RW020 gp140⌬CFI,
B_JRFL gp140CF, and C_96ZM651 gp140CF), CON6 gp140CF,
or empty plasmid control DNA (three times) at 3-week intervals
and boosted once with corresponding rVVs. To evaluate the
cross-reactive T-cell responses induced by the CON6 immunogen
in different genetic backgrounds with alternative MHC haplotypes, we determined T-cell responses in three mouse strains
(BALB/c, C57BL/6, and C3H-NeJ). Splenocytes from mice immunized with each immunogen were used according to the
numbers of INF-␥ spot-forming cells with five overlapping WT
Env peptide sets: 92UG37 (subtype A), SF162P3, MN and 89.6
(subtype B), and Chn19 (subtype C).
First, we determined the overall T-cell responses to peptide
pools containing all Env peptides for each subtype peptide set
with splenocytes from individual mice. In general, CON6 induced a similar magnitude of T-cell responses compared to

those induced by WT or polyvalent immunogens (Fig. 1). In
some instances, the T-cell responses induced by CON6 or the
polyvalent vaccine were more potent than those induced by the
various subtype immunogens. For example, CON6 induced
more potent T-cell responses than A_92RW020, C_96ZM651,
and the polyvalent immunogen in C57BL/6 mice (Student’s t test:
P ⫽ 0.001, P ⫽ 0.023, and P ⫽ 0.040, respectively), although these
differences were not seen in C3H and BALB/c strains.
To determine the breadth of the T-cell responses, we
mapped T-cell epitopes for each immunogen. We combined
splenocytes from all five mice in each group for the initial
screening using peptide pool matrices (1, 20) because the number of splenocytes from each mouse was insufficient for
epitope mapping with all five overlapping peptide sets.
When potential positive peptides were identified, we then
determined which peptides contained the T-cell epitopes
using individual peptides.
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In BALB/c mice immunized with the polyvalent immunogen
containing A, B, and C Envs, we found broader cross-subtype
T-cell responses (six, three, and five epitopes for subtypes A, B,
and C, respectively) compared to individual WT subtype immunogens (Fig. 2A and see Fig. S1 in the supplemental material). Importantly, we observed comparable broad cross-reactive T-cell responses with the single CON6 env immunogen
compared to the polyvalent vaccine (seven, three, and six
epitopes for subtypes A, B, and C, respectively). Three
epitopes (B1, B6, and B7) that were not detected in CON6immunized mice were only recognized by one subtype immunogen. Overall, among 12 T-cell epitopes identified in
BALB/c mice, individual subtype A, B, and C immunogens
failed to elicit T-cell responses to four, eight, and seven
epitopes, respectively, while CON6 and the polyvalent immunogens only missed three and two epitopes, respectively. However, eight epitopes were only detected in one of the two
repeats in mice immunized with the polyvalent immunogen
(Fig. 2A).
In C57BL/6 mice, we identified a total of nine T-cell
epitopes (Fig. 2B). CON6 Env performed well as an immunogen, with immunized animals failing to recognize only one
epitope (C3) among all epitopes identified in C57BL/6 mice.
Two epitopes (C1 and C7) were only detected in CON6-immunized mice. The WT subtype immunogens and the polyvalent immunogen induced similar T-cell responses in C57BL
mice, with each missing three or four T-cell epitopes.
Finally, in C3H-NeJ mice, we detected a total of seven
epitopes. Broader T-cell responses were induced by CON6 and
the polyvalent immunogen than single WT env genes (Fig. 2C).
All epitopes induced by individual subtype immunogens were
detected in the polyvalent group. The T-cell responses induced
by CON6 env missed two epitopes (H4 and H7) which were
subtype B or C specific. One additional epitope (H3) induced
in CON6-immunized mice was not detected with WT subtype
or polyvalent immunogens. B_JRFL induced similar T-cell responses to the polyvalent immunogen. Immunogen and peptide sequences corresponding to all potential T-cell epitopes
are summarized in Fig. 3 (and see Table S1 in the supplemental material).
To determine whether responding T cells were either CD8⫹
or CD4⫹, we performed ELISpot assays with either depleted
CD4⫹ or CD8⫹ T cells for all positive peptides in three mouse
strains. Four epitopes (B6, C1, C7, and C8) were recognized by
CD8⫹ T cells in BALB/c or C57BL/6 mice. All other epitopes
were recognized by CD4⫹ T cells (Fig. 2).
Since relatively small numbers of T-cell epitopes were identified for each immunogen in each mouse strain, we statistically
analyzed the breadth of T-cell responses among CON6, the
three subtype A, B, or C monovalent immunogens, and the
polyvalent immunogens by combining all T-cell epitopes from
three mouse strains with models that include the mouse strain
as a variable. To most reliably reveal the relationship among
the T-cell responses induced by each immunogen, we took the
following variables into consideration in our statistical model:
immunogens (n ⫽ 5), epitopes (n ⫽ 28), peptide sets (n ⫽ 5),
mouse strains (n ⫽ 3), and positive responses. Logistic regression (2, 8) is a natural strategy to use when asking a question
of this type: how the probability of a positive response depends
on the properties of the immunogen and the peptide. Such
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regression models yield a set of predicted probabilities as well
as a list of coefficients that permit one to compute odds ratios
and assign P values. For comparison, we classified the responses into four classes: (i) CON6 (responses induced by
CON6 determined by peptides from subtypes A, B, and C); (ii)
polyvalent (responses induced by the polyvalent immunogen
determined by peptides from subtypes A, B, and C); (iii) intraclade (responses induced by a single subtype immunogen
determined by peptides from the same subtype); and (iv) interclade (responses induced by a single subtype immunogen
determined by peptides from the other subtypes). We also
considered two definitions of whether a given peptide induced
a positive response when tested against a given immunogen: in
the first, we treated each reaction, including repeats, separately, classifying a response as positive if we saw 50 or more
SFC per million cells. For the second definition, we based our
judgment on all the repeats of a single peptide-epitope combination, declaring the response to be positive if any one of the
repeats showed 50 or more SFC per million cells. Our analysis
showed that the immunogen type significantly influenced the
probability of positive response. Under the first definition, the
CON6 immunogen was most likely to produce a positive response, followed by polyvalent ⫽ intraclade ⬎ interclade. In
this sense, CON6 was significantly more likely to induce a
positive response than the polyvalent immunogen (odds ratio,
⬎1.89; P ⬍ 0.005) and interclade responses were significantly
diminished compared to the polyvalent responses (odds ratio,
⬍ 0.56; P ⬍ 0.002). With the alternative definition (any single
positive reaction implies positivity), the differences between
the immunogens were less pronounced: the CON6, polyvalent,
and intraclade responses were all comparable, and the only
statistically significant effect was the markedly reduced probability of a positive response induced by interclade immunogens
(odds ratio, ⬍0.4; P ⬍ 0.0004). The modeling results from this
second definition are in good qualitative agreement with the
broad picture of induced response, in which T-cell responses to
the CON6 and polyvalent immunogens were similar, with 22 total
epitopes recognized by the polyvalent immunogen-immunized
mice and 22 total epitopes recognized by CON6-immunized mice.
Finally, we also explored the dependence of breadth of Tcell response on mouse strain, including this as an extra explanatory factor. With the first, reaction-by-reaction, definition
of a positive response, the strongest effect is that the C3H mice
are much more likely to produce a positive response than the
others (odds ratio, ⬎9.25; P ⬍ 0.004). This model was, however, the only one of those presented here that was overdispersed (estimated deviance of 1.8 per degree of freedom),
suggesting that this model failed to capture some important
source of variation. In contrast, when we fit a similar model,
but used the second sense of positivity (any positive response
among the duplicate reactions implies positive), a more consistent story emerged: the C3H mice still proved more likely to
exhibit a positive response, but the effect was less significant
(odds ratio, ⬎14.1; P ⬍ 0.015). The only other significant
effects were a modestly significant enhancement in the response of C57BL/6 mice to epitopes of subtype B (odds ratio,
⬎3.4; P ⬍ 0.017) and a highly significant decrease in probability of a response for interclade epitopes (odds ratio, ⬍0.37;
P ⬍ 0.0002).
Taken together, we believe that the most appropriate con-
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FIG. 2. T-cell epitope mapping of CON6 and subtype Env immunogens. T-cell responses were determined in three mouse strains with five
overlapping Env peptide sets from subtypes A, B, and C (A_92UG37, B_SF162P3, B_89.6, B_MN, and C_Chn19). For direct comparison to subtype A
and C peptide sets, results from only one (B_SF162P3) of the three subtype B peptide sets are shown in the figure. The T-cell epitopes were first screened
with Env overlapping peptide matrices and then confirmed with individual peptides by ELISpot analysis. Positive subtype A, B, and C epitopes are
indicated by blue, red, and green boxes, respectively. Epitopes that were positive once in two repeats are indicted with boxes composed of colored and
white triangles. White boxes indicate the epitopes that were expected to be detected but did not induce ⬎50 SFC. Epitopes starting with the letters B,
C, and H represent the epitopes from BALB/c (A), C57BL/6 (B), and C3H-NeJ (C) mice, respectively. CD8 epitopes are indicated by asterisks, and all
others are CD4 epitopes. A deletion containing the C8 epitope between HR1 and HR2 in the gp41 region of 92RW020 (22) is indicated.
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FIG. 3. Potential T-cell epitope sequence alignment of the immunogens and screening peptides. All sequences were compared to the group M
consensus Env sequence (CON6). Sequences of potential T-cell epitopes from immunogens are shown at the top, and sequences of the peptides
used for epitope mapping are shown at the bottom for each mouse strain. Epitopes starting with the letters B, C, and H stand for the epitopes from
BALB/c (A), C57BL/6 (B), and C3H-NeJ (C) mice, respectively. Peptides that are positive for any one of the three subtypes are underlined.
Mutations in the immunogens that might be responsible for failure to induce T-cell responses are indicated by bold letters.

clusion from our statistical analyses is that the group M consensus env immunogen induced similar breadth to the polyvalent immunogen and was superior to individual WT env
immunogens.
Magnitude of cross-subtype T-cell immune responses induced by CON6. We measured the intensity of the T-cell responses induced by each immunogen with pooled peptides
(over 72 peptides in each reaction) (Fig. 1). In these analyses,
a pooled response could be dominated by the immunodominant response and responses might also be subjected to interference among peptides in the pool. We obtained the T-cell
responses to individual peptides. This allowed us to perform a
comparison of distributions of the potencies of T-cell responses induced by each epitope to the different vaccines. All
SFC numbers for peptides for each immunogen were plotted in
four groups as classified earlier: CON6, polyvalent, intraclade,
and interclade (Fig. 4). When multiple counts were available
for an epitope (because overlapping peptides were considered
to represent a single response and repeats for the same
epitope), the highest SFC numbers were used systematically as

the single data point included in the analysis. Comparable
ELISpot numbers were induced by different immunogens for
the shared epitopes, suggesting all immunogens had similar
capabilities to induce the T-cell responses.
The Kruskal-Wallis rank sum test was used to compare distributions of response levels to peptides found in the four
groups. The null hypothesis—that all four sets of values were
drawn from the same distribution—was found to be very unlikely (P ⫽ 0.0000025), so we went on to do pairwise comparisons between groups using a Wilcoxon rank sum statistic. This
potency comparison analysis showed CON6-immunized animals had slightly better responses than polyvalent immunogenimmunized animals, with polyvalent ⫽ intraclade ⬎ interclade.
About the same number of peptides that induced no response
(nonstimulators; ⬍50 SFC) were found in the CON6, polyvalent, and intraclade groups (Fig. 4A), but many more nonstimulators were found in the interclade group. When only
positive ELISpot counts were used for the comparison, the
potency of T-cell responses induced by CON6 was still stronger
than those of all other groups (Fig. 4B). We then reevaluated
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FIG. 4. Potency of T-cell immune responses among consensus and
subtype Env immunogens. T-cell responses (SFC/106 cells) are plotted for
each peptide that yielded at least one positive response (⬎50) to at least
one of the five immunogens (A_92UG037, B_JRFL, C_96ZM651,
CON6, and polyvalent). Four groups of responses were compared: (i)
within clade (responses induced by WT subtype immunogen determined by peptides from the same subtype), (ii) between clade (responses induced by WT subtype immunogen determined by peptides
from the other subtypes), (iii) CON6 (responses induced by CON6
determined by peptides from subtypes A, B, and C), and (iv) polyvalent (responses induced by the polyvalent immunogen determined by
peptides from subtypes A, B, and C). Each dot represents an SFC
count. The dashed line indicates the threshold (50 SFC) below which
responses were considered negative. The interquartile ranges and medians are indicated by the black vertical bars and white lines in the
bars. The statistical comparison was performed using the KruskalWallis and the Wilcoxon rank tests. The Wilcoxon rank P values are
shown for the compared groups.
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this comparison for each mouse strain independently. With the
smaller number of positive scores available when comparing
the results of each strain, the only comparisons that remained
significant were the generally higher magnitude of CON6 responses in C57BL/6 mice compared to the polyvalent vaccine
(P ⫽ 0.0047), intraclade (P ⫽ 0.011), and interclade (P ⫽
0.000027) responses.
We then performed a second analysis of the data, to directly
compare the magnitudes of response to specific peptides rather
than the distributions of levels of response. We classified the
responses elicited by immunogens against each of the 88 peptides that had detectable responses in at least one vaccinated
animal by ranking the level of response to that peptide elicited
by each immunogen. The immunogens were categorized three
ways for each peptide to ascertain which immunogen tended to
give the strongest responses. The three categories were (i) the
immunogen with the strongest score for a given peptide (strongest response), (ii) the immunogens that gave a positive score
but not the strongest score (positive response), or (iii) the
immunogens that had no detectable response to the peptide
(no reaction; ⬍50 SFC). In this analysis, CON6 had the highest
frequency of the strongest score responses and the lowest frequency of no-reaction responses (Fig. 5A). In contrast, the
lower frequencies of strongest score responses were observed
for polyvalent, intraclade, and interclade groups. A 3-by-4 contingency table showed that the frequencies were unlikely to be
observed by chance (P ⫽ 0.0000066), and separate 2-by-3 comparisons showed that the distributions were distinct for CON6
versus polyvalent (P ⫽ 0.00008), CON6 versus intraclade (P ⫽
0.0072), and intraclade versus interclade (P ⫽ 0.0086). No
significant differences were observed between polyvalent and
intraclade groups (P ⫽ 0.44).
We next compared the potencies of T-cell responses for each
subtype immunogen. Single subtype A, B, and C natural antigens gave comparable levels of intraclade responses to the
heterologous antigens. No significant differences were observed when T-cell responses induced by subtype immunogens
were measured with heterologous peptides from the same subtype (Fig. 5B). However, when heterologous peptides from
different subtypes were used to measure T-cell responses, the
subtype A immunogen (A_92RW020) had more strongest responses than subtype B or C immunogens (Fig. 5C).
Given the heterogeneity of responses seen between mouse
strains, we believe the appropriate interpretation of our analyses is that the group M consensus immunogen induced responses that were comparable in potency to those of the polyvalent immunogen and superior to those of the individual WT
immunogens.
Similar T-cell responses induced by subtype B and CON6
Env immunogens to three heterologous subtype B overlapping
Env peptide sets. We used three available heterologous subtype B Env overlapping peptide sets (MN, 89.6, and SF162P3)
to determine cross-reactive T-cell responses induced by the
subtype B, other subtype, or consensus immunogens. Table 2
shows that more T-cell epitopes (16) were detected in mice
immunized with subtype immunogen B_JRFL than in those
immunized with A_92RW020 (11) or C_96ZM651 (10). In
B_JRFL-immunized mice, only a few epitopes were detected
with all three subtype B peptides in either BALB/c mice (two
out of five) or C3H mice (one out of six), although all five
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FIG. 5. Intensity of T-cell immune responses among consensus and
subtype Env immunogens by rank. The same data in Fig. 4 were used
for comparison by classifying the responses in three categories: (i) the
immunogen with the strongest score for a given peptide (strongest
response); (ii) the immunogens that gave a positive score, but not the
strongest score (positive response); and (iii) the immunogens that had
no detectable response to the peptide (no reaction; ⬍50 SFC). The
same four groups (within clade, between clade, CON6, and polyvalent)
as in Fig. 4 were compared (A). The T-cell responses within the
subtype (B) and between subtypes (C) for each WT subtype immunogen were also compared. The 3-by-4 and 2-by-3 contingency table tests
were performed for statistical comparisons.

T-cell epitopes were identified with peptides from all three
subtype B sets in C57BL/6 mice. CON6 induced similar T-cell
responses to three subtype B peptide sets, as did B_JRFL in
terms of total numbers of T-cell epitopes or numbers of crossreactive epitopes (Table 2 and see Fig. S2 in the supplemental
material).
Failure to detect T-cell responses due to mutations in T-cell
epitopes. In the above analyses, we observed that T-cell responses were not always detected among all immunogens or by
corresponding peptides. Failures to detect T-cell responses
were of two types that were readily understood: those due to
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amino acid substitutions in screening peptides and those due to
amino acid substitutions in immunogens. In the first type, the
T-cell response was induced by the immunogen but was not
detected when screened with the peptides carrying one or
more mutations (Fig. 3). For example, an E-to-D substitution
was found in the Chn19 peptide in the C4 epitope in C57BL/6
mice (Fig. 3B). No T cells from any group of immunized mice
recognized this peptide (Fig. 2 and see Fig. S1 in the supplemental material). A similar phenomenon has been observed by
others for the Th epitope (FEPIPIHYC), in which the E-to-D
substitution abrogated T-helper hybridomas’ ability to recognize the mutant peptide (40). Some peptides with amino acid
substitutions did not completely fail to induce T-cell responses,
but the substitutions significantly decreased the peptides’ ability to stimulate SFC in vitro. For example, the SFC numbers
induced by SF162P3 P18 equivalent peptide with an R-to-K
substitution (B6) were at least fivefold lower than those induced by corresponding MN or 89.6 peptides (data not shown).
In the second case, the immunogens containing an amino
acid substitution or substitutions in the T-cell epitope regions
did not induce T-cell responses for the corresponding epitope
responses. For example, in BALB/c and C57BL/6 mice, highly
conserved and cross-reactive B2 and C2 epitopes were not
detected when A_92RW020 was used as the immunogen, while
both epitopes were induced by other immunogens (Fig. 2 and
3). The A-to-E substitution in either the B2 or C2 epitope in
the A_92RW020 immunogen sequence might be responsible
for the failure to elicit the corresponding T-cell response (Fig.
3A and B).
To determine the potential T-cell epitope coverage of each
immunogen, all possible 9-mers in the proteins were compared
between the vaccines and the test peptides. CON6 and intraclade single sequences had a similar coverage (27% and 28%,
respectively) of the 9-mers in test peptide sequences. The single sequences in the interclade group had the poorest coverage
(15%). However, when three sequences were included in the
polyvalent immunogen, substantially more 9-mers (37%) were
matched among the test peptides (Table 3). Similar results
were obtained using 11-mer peptide sequences (Table 3).
Given the analysis of 9-mer and 11-mer coverage, it was expected that the polyvalent immunogen would elicit more detectable responses than CON6, but this was not what we observed. This might be explained by the generally diminished
magnitude of responses to the polyvalent vaccine reducing our
ability to discern responses near the threshold of detection. In
the polyvalent group, a few epitopes were not detected (white
boxes in Fig. 2) that were induced by individual subtype immunogens. Failure to detect T-cell responses to these peptides
in the polyvalent group could not be explained by amino acid
substitutions in either immunogens or peptides used for
screening, since the same subtype immunogens and peptides
were positive when they were tested as individual subtype immunogens (Fig. 2 and 3). Also, often only one of two ELISpot
repeats was positive for the polyvalent vaccine. This lack of
reactivity may be due to the lower dose of each immunogen
(1/3 of individual subtype immunogen doses) in the mixture,
interference among epitopes from three subtype immunogens
in the mixture (18, 21), or other mechanisms.
Most of the T-cell epitopes of HIV-1 envelope proteins were
in conserved regions. To determine the locations of all iden-
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TABLE 2. Cross-reactive T-cell epitopes identified with three subtype B peptide sets (MN, 89.6, and SF162P3)
Subtype B peptides T-cell epitopes respond toa:
Immunogen

BALB/c
3

2

B_JRFL

B5
B6

A_92RW020

B4
B5
B9
B11

C_96ZM651

B9

B2

CON6

B2
B9

B4

a

B1
B2

C57BL/6
1

3

2

1

3

2

1

H1
H4

H2
H6
H7

16

H2

11

B4

C2
C4
C5
C6
C8

H5

B7

C4
C5
C6

H5
H6

C6

B10

Total no. of
epitopes

C3H

C2
C4
C5

C2
C4
C5
C6
C8

C7

H5
H6

H1

H2

10

H5
H6

H1

H2
H3

15

Numbers 3, 2, and 1 represent the number of peptides responded to.

tified T-cell epitopes in the Env proteins, we mapped epitopes
from three mouse strains (Fig. 6). Most of the epitopes were
found in the conservative regions of the envelope protein, with
only a few exceptions. One epitope (C1) in C57BL/6 mice
immunized with CON6 was found in the signal peptide region.
It was only detected with Chn19 peptides and not with any
others due to the high level of sequence variation (Fig. 3B).
The same epitope was also confirmed with CON6 autologous
peptides (data not shown). In BALB/c mice, a well-studied
subtype B-specific P18 epitope (B6) was confirmed in the V3
region (35), which was actually not much more variable than
other conserved regions in the Env proteins (Fig. 3A) (16).
Epitopes B3 and C7 overlapped with the 3⬘ end of V3 and 5⬘
end of V4, respectively. However, both overlapping regions
were conserved. We did not have autologous peptide sets for

each subtype immunogen to map potential T-cell epitopes in
the variable regions. However, we mapped the T-cell epitopes
for CON6 with autologous overlapping peptides and found
only one extra epitope in C57BL/6 mice and one extra epitope
in C3H mice. Both were in the conserved regions (data not
shown). Parts of variable regions (V1, V2, V4, and V5) in
CON6 were from a subtype C Env sequence. However, we did
not observe more cross-reactive T-cell responses to subtype C
peptides (Chn19) despite greater similarity in the variable regions between CON6 and Chn19 sequences.
Three murine T-cell epitope hot spots were found in the
gp140 protein (Fig. 6). The first one was at the N terminus of
gp120 (B1, B2/C2, H1, and H2). The second one was at the first
half of the C2 region (B3/C3, B4/C4, C5, and B5). The third
one was at the gp41 heptad repeat region (H3, B9/H4, B10/H5,

TABLE 3. Amino acid similarity of all possible 9- or 11-mer peptide sequences between immunogens and peptides used in this study
Relative amino acid similarity e
No. of mismatches in peptide

CON6a

A⫹B⫹C b

Intracladec

Intercladed

Peptide match length of 9
0
1
2
3

0.2674 ⫾ 0.0147
0.5423 ⫾ 0.0144
0.7177 ⫾ 0.0232
0.8310 ⫾ 0.0224

0.3703 ⫾ 0.0234
0.6262 ⫾ 0.0203
0.7679 ⫾ 0.0120
0.8435 ⫾ 0.0094

0.2822 ⫾ 0.0356
0.5356 ⫾ 0.0293
0.6886 ⫾ 0.0245
0.7743 ⫾ 0.0215

0.1532 ⫾ 0.0100
0.3709 ⫾ 0.0126
0.5592 ⫾ 0.0078
0.7133 ⫾ 0.0070

Peptide match length of 11
0
1
2
3

0.2078 ⫾ 0.0159
0.4682 ⫾ 0.0134
0.6430 ⫾ 0.0224
0.7665 ⫾ 0.0277

0.3076 ⫾ 0.0229
0.5538 ⫾ 0.0270
0.7103 ⫾ 0.0154
0.7927 ⫾ 0.0117

0.2291 ⫾ 0.0355
0.4686 ⫾ 0.0342
0.6263 ⫾ 0.0269
0.7190 ⫾ 0.0267

0.1080 ⫾ 0.0101
0.2945 ⫾ 0.0137
0.4730 ⫾ 0.0078
0.6238 ⫾ 0.0087

a

CON6, the CON6 immunogen sequence was compared to subtype A, B, and C peptide sequences.
A⫹B⫹C, all three sequences in the polyvalent immunogen were compared to subtype A, B, and C peptide sequences.
Intraclade, the individual subtype immunogen sequence was compared to subtype matching peptide sequences.
d
Interclade, the individual subtype immunogen sequence was compared to subtype mismatching peptide sequences.
e
The data are shown as mean ⫾ standard error relative to 1 ⫽ 100%.
b
c
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FIG. 6. The locations of T-cell epitopes in gp140 protein detected in all three mouse strains. The signal peptide (SP), variable regions, and
heptad repeats (HR1 and HR2) are indicated by hatched, solid, and empty boxes, respectively. The deletion of the gp120/gp41 cleavage site and
the fusion domain of gp41 are indicated by an arrow. The deletion of the spacer between HR1 and HR2 is indicated by an asterisk. The three T-cell
epitope hot spots are indicted at the bottom of the figure. CD8 epitopes are indicated by boxed epitopes; all others were CD4 epitopes.

B11/H6, B12, C8, H7, and C9). All epitopes in each hot spot
were localized in close proximity to each other (Fig. 3 and 6).
These results suggested that these regions may be major T-cell
response targets in mice.
DISCUSSION
In this study, we demonstrated that the group M consensus
env gene (CON6) induced a higher number of cross-reactive
and more potent T-cell responses to subtype A, B, and C
viruses than any single subtype env immunogen alone. CON6
induced cross-reactive T-cell responses to all three subtypes,
while single WT clade A, B, or C immunogens tended to
induce subtype-specific T-cell immune responses and induced
fewer responses that were cross-reactive with other subtypes.
Interestingly, the polyvalent immunogen induced similar numbers of epitope responses compared to CON6. While we recognize that immunogenicity of an immunogen in mice does not
necessarily predict immunogenicity in nonhuman primates or
humans, these results provide proof of the concept that a
consensus immunogen can induce broader and more potent
T-cell responses across clades than individual strain-based immunogens. Thus, the theoretical advantages of the consensus
approach as a T-cell immunogen have been experimentally
validated in an animal model system. Further testing of centralized gene vaccines in nonhuman primates and humans,
alone or in combination with subtype consensus or WT immunogens, are thus warranted.
While it was anticipated that intraclade responses would be
more intense and more common than interclade responses, the
performance of the CON6 immunogen with respect to both the
breadth and magnitude of the elicited immune response was
not expected. Previous studies have shown that a polyvalent
immunogen induces broader immune responses than single
immunogens (6, 7, 22, 34). In two studies, the T-cell responses
were analyzed with peptide pools but not individual peptides
(22, 34). In such an analysis, a few predominant T-cell responses might overshadow many weaker T-cell responses and
the breadth of T-cell responses could not be evaluated on the
basis of individual T-cell epitopes. In the current study, we

defined T-cell epitopes using individual peptides from five
overlapping Env peptide sets of three subtypes (A, B, and C)
and found that the majority of the T-cell epitopes were recognized by responses elicited by the polyvalent immunogen.
However, some T-cell epitopes were not detected in mice immunized with the polyvalent immunogen, while the same
epitopes were detected in the animals immunized with individual subtype immunogens. The failure to induce some T-cell
responses might be due to the lower doses of each immunogen
in the polyvalent cocktail. Alternatively, there may have been
interference between some of the epitopes among the multiple
immunogens. Interference has been reported in some (17, 22,
34) but not all (18, 21) studies of multivalent immunogens, thus
leaving its potential impact on our results unclear. Still another
explanation may be that the ancestral nature of CON6 (group
M consensus and ancestor sequences being the same in this
case) (13, 14) may have features that make it more immunogenic, while some of these immune responses have been lost in
modern strains that may have accumulated immunorefractive
mutations as HIV has evolved in people. While HLA and
MHC molecules are very different in humans and mice, the
processing of T-cell epitopes by enzymes may not be.
A recent study by Doria-Rose et al. showed that an ancestral
subtype B env immunogen (An1-envB) induced weak neutralizing activity in rabbits (10). We have observed neutralizing
activity induced with CON6 gp120 and gp140 proteins in
guinea pigs similar to those induced by An1-envB (15). The
study by Doria-Rose et al. did not perform T-cell immune
response analysis. In a more recent study, we have studied a
second generation of group M consensus Env immunogen
(CON-S) with shorter variable loops for its ability to induce
neutralizing antibodies and discovered that a newer generation
of group M consensus env gene (CON-S) with shorter variable
loops can induce broader neutralizing antibody responses to
subtype B and C viruses than wild-type Env immunogens (27).
This study showed that the consensus gene approach has potential for inducing more broadly reactive neutralizing antibodies than current immunogens and was superior to wild-type
subtype A, B, or C primary HIV-1 Envs. Further studies are
needed to compare the neutralizing antibody responses in-

VOL. 80, 2006

duced by the group M consensus env gene with a large panel of
polyvalent Env immunogens.
Few studies have been performed to map T-cell epitopes
with single overlapping Env peptide sets in mice (5, 9, 37, 40).
T-cell epitopes in each subtype WT Env protein used in this
study have not been identified before. Our study is the first to
systemically map the Env T-cell epitopes induced by consensus
and multiple subtype Env immunogens with different subtype
overlapping peptide sets. In the Los Alamos HIV Molecular
Immunology Database, many CD4 epitopes were registered
from the literature but only four CD8 epitopes were reported
in mice (23). In this study, we identified three new CD8
epitopes (C1, C7, and C8) in C57BL/6 mice and four new CD4
epitopes (B9/H3, B10/H4, H7, and C9) in three strains of mice,
although we did not detect some CD4 epitopes that have been
previously reported (23).
The majority of T-cell epitopes identified in this study were
in conserved envelope regions (Fig. 6). These data differed
from results from other studies in which Th epitopes were
identified in envelope variable regions (9, 37). This discrepancy
may be partly explained by the use of different immunogens,
peptides, and detection methods of Th responses. However,
Yusim et al. showed that HIV CTL epitopes were concentrated in relatively conserved regions when heterologous reference peptides were used for detection of CTL activity (39).
They also found that variable regions tend to have higher
concentrations of amino acids that never serve as C-terminal
anchor residues and to have reduced propensity for epitope
cleavage and processing. The analysis suggests that variable
regions that more readily accommodate changes in HIV-1 genomes tend to accumulate mutations that make them generally
less immunogenic as well as less likely to be cross-recognized
either within a subtype or among subtypes. Thus, the sequence
analysis is in agreement with our observation.
Based on the crystal structure of gp120 protein (25), we
found most of the Th epitope targets (H1, H2, C3/B3, C4/B4,
C5, B5, and B8) were in the nonexposed inner domain and only
three Th epitope targets (C6, C7, and B7) were in the outer
domain. Other Th epitope targets were in either the signal
peptide region (C1) or the C1 region (B1 and B2/C2), for
which no structural data were available. Therefore, our data do
not support the hypothesis that exposed protein fragments are
uniquely susceptible to proteolytic activity and are thus preferentially shuttled through the antigen-processing pathway in
mice (5, 37).
T-cell responses were sensitive to amino acid substitutions
between immunogens and peptides, and nearly all nonrecognized T-cell epitopes had amino acid substitutions in the
epitope sequences in the vaccines relative to testing strains.
This was also true for the subtype B immunogen (JRFL) when
three heterologous subtype B Env overlapping peptide sets
were used for epitope mapping. Since vaccinated individuals
will not be exposed to, nor infected with, homologous viruses,
a successful vaccine must be able to prevent or control heterologous viral infection. Therefore, our study with heterologous
immunogens and screening peptides within the same subtype
was designed to begin to mimic this viral diversity. The level of
cross-reactivity induced by the subtype B immunogen to three
heterologous subtype B Env-overlapping peptide sets was similar to what we observed with CON6 immunogen (Table 2).
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Our sequence analysis showed that the differences in amino
acid sequences between group M consensus and subtype Env
proteins were the same as those between two viruses within the
same subtype (Table 1) (14). Therefore, our experimental results were in agreement with our expectations based on sequence analysis and suggest that the group M consensus immunogens may be as efficient as a natural appropriately
selected single subtype immunogen for induction of T-cell immune responses against viruses in regions where one subtype is
predominant.
The inbred mouse is not an ideal model with which to study
T-cell responses, since mice from the same strain have a common genetic background and mouse MHC molecules are different from HLA molecules in humans. The other major difference is that viruses constantly evolve under the immune
selection pressure and accumulate many escape mutations
along infection history in humans, while they are completely
new in mice when used as immunogens. However, if the mechanisms for T-cell responses to HIV-1 immunogens in general
are similar between humans and mice, more cross-reactive
T-cell responses after immunization with group M consensus
immunogens might be anticipated in humans, although the
T-cell epitopes recognized may be different. To address this
concern, a similar comparison experiment is warranted to determine if cross-subtype T-cell responses can also be induced
in nonhuman primates and, if successful, in human clinical
trials.
ACKNOWLEDGMENTS
We thank Allan Zajac for stimulating discussions, Thomas Kepler
for statistical analyses and perspective, Stacie Vanleeuwen for technical assistance, Olga Torres for artwork, and the Los Alamos National
Laboratory Advanced Computing Laboratory for providing parallel
computing time used to inform the design of the group M consensus
sequence (CON6).
This work was supported by NIH, NIAID grants AI85338, AI54497,
AI55386, PO1 AI52816, IPCAVD AI35351, and HIVRAD AI61734;
Duke Center for Translational Research grant AI51445; and the
NIAID AIDS Research and Reference Reagent Program. E.A.W. and
Z.T.C. were supported by NIH training grant 5T32 AI07392. B.T.K.
was funded through internal Los Alamos National Laboratory LDRD
research funds.
REFERENCES
1. Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N.
Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, M. E. Feeney, W. R.
Rodriguez, N. Basgoz, R. Draenert, D. R. Stone, C. Brander, P. J. Goulder,
E. S. Rosenberg, M. Altfeld, and B. D. Walker. 2003. Comprehensive epitope
analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell
responses directed against the entire expressed HIV-1 genome demonstrate
broadly directed responses, but no correlation to viral load. J. Virol. 77:2081–
2092.
2. Agresti, A. 2002. Categorical data analysis. John Wiley & Sons, Inc., Hoboken, N.J.
3. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O’Neil, S. I.
Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A.
Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L.
Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L.
Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by
a multiprotein DNA/MVA vaccine. Science 292:69–74.
4. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W.
Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A.
Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S.
Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S.
Gelman, D. C. Montefiori, M. G. Lewis, E. A. Emini, J. W. Shiver, and N. L.
Letvin. 2000. Control of viremia and prevention of clinical AIDS in rhesus
monkeys by cytokine-augmented DNA vaccination. Science 290:486–492.
5. Brown, S. A., J. Stambas, X. Zhan, K. S. Slobod, C. Coleclough, A. Zirkel, S.
Surman, S. W. White, P. C. Doherty, and J. L. Hurwitz. 2003. Clustering of

6756

6.

7.

8.
9.

10.

11.

12.

13.

14.

15.

16.
17.

18.
19.

20.

21.
22.
23.
24.

WEAVER ET AL.

Th cell epitopes on exposed regions of HIV envelope despite defects in
antibody activity. J. Immunol. 171:4140–4148.
Chakrabarti, B. K., X. Ling, Z. Y. Yang, D. C. Montefiori, A. Panet, W. P.
Kong, B. Welcher, M. K. Louder, J. R. Mascola, and G. J. Nabel. 2005.
Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23:3434–3445.
Cho, M. W., Y. B. Kim, M. K. Lee, K. C. Gupta, W. Ross, R. Plishka, A.
Buckler-White, T. Igarashi, T. Theodore, R. Byrum, C. Kemp, D. C.
Montefiori, and M. A. Martin. 2001. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide
sterilizing protection against heterologous simian/human immunodeficiency
virus infection in pigtailed macaques. J. Virol. 75:2224–2234.
Crawly, M. 2002. Statistical computing: an introduction to data analysis using
S-Plus. John Wiley & Sons, Inc., Chichester, West Sussex, United Kingdom.
Dai, G., N. K. Steede, and S. J. Landry. 2001. Allocation of helper T-cell
epitope immunodominance according to three-dimensional structure in the
human immunodeficiency virus type I envelope glycoprotein gp120. J. Biol.
Chem. 276:41913–41920.
Doria-Rose, N. A., G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M.
Mahalanabis, M. T. Hensel, S. McLaughlin, P. F. Edmonson, D. Montefiori,
S. W. Barnett, N. L. Haigwood, and J. I. Mullins. 2005. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and
elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79:11214–11224.
Ellenberger, D. L., B. Li, L. D. Lupo, S. M. Owen, J. Nkengasong, M. S.
Kadio-Morokro, J. Smith, H. Robinson, M. Ackers, A. Greenberg, T. Folks,
and S. Butera. 2002. Generation of a consensus sequence from prevalent and
incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 302:155–163.
Ferrari, G., W. Humphrey, M. J. McElrath, J. L. Excler, A. M. Duliege, M. L.
Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade
B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities
in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396–1401.
Ferrari, G., D. D. Kostyu, J. Cox, D. V. Dawson, J. Flores, K. J. Weinhold,
and S. Osmanov. 2000. Identification of highly conserved and broadly crossreactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
AIDS Res. Hum. Retrovir. 16:1433–1443.
Gao, F., T. Bhattacharya, B. Gaschen, J. Taylor, J. P. Moore, V. Novitsky, K.
Yusim, D. Lang, B. Foley, S. Beddows, M. Alam, B. Haynes, B. H. Hahn, and
B. Korber. 2003. Consensus and ancestral state HIV vaccines. Science 299:
1517–1518. (Letter.)
Gao, F., E. A. Weaver, Z. Lu, Y. Li, H.-X. Liao, B. Ma, S. M. Alam, R. M.
Scearce, L. L. Sutherland, J.-S. Yu, J. M. Decker, G. M. Shaw, D. C.
Montefiori, B. T. Korber, B. H. Hahn, and B. F. Haynes. 2005. Antigenicity
and immunogenicity of a synthetic human immunodeficiency virus type 1
group M consensus envelope glycoprotein. J. Virol. 79:1154–1163.
Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B.
Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354–2360.
Haynes, B. F., M. A. Moody, C. S. Heinley, B. Korber, W. A. Millard, and
R. M. Scearce. 1995. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent
immunogen. AIDS Res. Hum. Retrovir. 11:211–221.
Insel, R. A. 1995. Potential alterations in immunogenicity by combining or
simultaneously administering vaccine components. Ann. N. Y. Acad. Sci.
754:35–47.
Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E.
Irwin, J. T. Safrit, J. Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S.
Perelson, and D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8(⫹)
T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp.
Med. 189:991–998.
Keating, S. M., R. C. Bollinger, T. C. Quinn, J. B. Jackson, and L. M.
Carruth. 2002. Cross-clade T lymphocyte-mediated immunity to HIV type 1:
implications for vaccine design and immunodetection assays. AIDS Res.
Hum. Retrovir. 18:1067–1079.
Kjerrstrom, A., J. Hinkula, G. Engstrom, V. Ovod, K. Krohn, R. Benthin,
and B. Wahren. 2001. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284:46–61.
Kong, W.-P., Y. Huang, Z.-Y. Yang, B. K. Chakrabarti, Z. Moodie, and G. J.
Nabel. 2003. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77:12764–12772.
Korber, B., C. Brander, B. Haynes, R. Koup, C. Kuiken, J. Moore, B. Walker,
D. Watkins, et al. 2002. HIV molecular immunology 2002. Los Alamos
National Laboratory, Los Alamos, N.Mex.
Korber, B., M. Muldoon, J. Theiler, F. Gao, R. Gupta, A. Lapedes, B. H.

J. VIROL.

25.

26.

27.

28.
29.

30.

31.

32.
33.

34.

35.

36.

37.

38.

39.

40.

Hahn, S. Wolinsky, and T. Bhattacharya. 2000. Timing the ancestor of the
HIV-1 pandemic strains. Science 288:1789–1796.
Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A.
Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in
complex with the CD4 receptor and a neutralizing human antibody. Nature
393:648–659.
Leitner, T., B. Foley, B. H. Hahn, P. A. Marx, F. McCutchan, J. W. Mellors,
S. Wolinksy, B. Korber, et al. 2004. HIV sequence compendium 2003. Los
Alamos National Laboratory, Los Alamos, N.Mex.
Liao, H. X., L. L. Sutherland, S.-M. Xia, M. E. Brock, R. M. Scearce, S.
Vanleeuwen, M. Alam, S. McAdam, E. Weaver, Z. T. Camacho, B. Ma, Y. Li,
J. Decker, G. J. Nabel, D. Montefiori, B. H. Hahn, B. Korber, F. Gao, and B.
Haynes. A group M consensus envelope glycoprotein induces antibodies that
neutralize subsets of subtype B and C HIV-1 primary viruses. Virology, in
press.
McCullagh, P., and J. Nelder. 1989. Generalized linear models. Chapman
and Hall, London, United Kingdom.
Moss, B., and P. Earl. 1998. Expression of proteins in mammalian cells using
vaccinia viral vectors, p. 16.15.1–16.19.9. In F. M. Ausubel, R. Brent, R. E.
Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.),
Current protocols in molecular biology. John Wiley & Sons, Inc., Indianapolis, Ind.
Nickle, D. C., M. A. Jensen, G. S. Gottlieb, D. Shriner, G. H. Learn, A. G.
Rodrigo, and J. I. Mullins. 2003. Consensus and ancestral state HIV vaccines. Science 299:1515–1517. (Letter.)
Novitsky, V., U. R. Smith, P. Gilbert, M. F. McLane, P. Chigwedere, C.
Williamson, T. Ndung’u, I. Klein, S. Y. Chang, T. Peter, I. Thior, B. T. Foley,
S. Gaolekwe, N. Rybak, S. Gaseitsiwe, F. Vannberg, R. Marlink, T. H. Lee,
and M. Essex. 2002. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J. Virol.
76:5435–5451.
R Development Core Team. 2005. A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria.
Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A.
Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb,
M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A.
Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8⫹ lymphocytes. Science 283:857–860.
Seaman, M. S., L. Xu, K. Beaudry, K. L. Martin, M. H. Beddall, A. Miura,
A. Sambor, B. K. Chakrabarti, Y. Huang, R. Bailer, R. A. Koup, J. R.
Mascola, G. J. Nabel, and N. L. Letvin. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79:2956–2963.
Shirai, M., C. D. Pendleton, and J. A. Berzofsky. 1992. Broad recognition of
cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class
I histocompatibility molecules. J. Immunol. 148:1657–1667.
Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans,
Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris,
R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V.
Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins,
G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm,
J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A.
Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C.
Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E.
Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and
E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits
effective anti-immunodeficiency-virus immunity. Nature 415:331–335.
Surman, S., T. D. Lockey, K. S. Slobod, B. Jones, J. M. Riberdy, S. W. White,
P. C. Doherty, and J. L. Hurwitz. 2001. Localization of CD4⫹ T cell epitope
hotspots to exposed strands of HIV envelope glycoprotein suggests structural
influences on antigen processing. Proc. Natl. Acad. Sci. USA 98:4587–4592.
Vidal, N., M. Peeters, C. Mulanga-Kabeya, N. Nzilambi, D. Robertson, W.
Ilunga, H. Sema, K. Tshimanga, B. Bongo, and E. Delaporte. 2000. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M
genetic diversity in the Democratic Republic of Congo suggests that the
HIV-1 pandemic originated in Central Africa. J. Virol. 74:10498–10507.
Yusim, K., C. Kesmir, B. Gaschen, M. M. Addo, M. Altfeld, S. Brunak, A.
Chigaev, V. Detours, and B. T. Korber. 2002. Clustering patterns of cytotoxic
T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1)
proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 76:8757–8768.
Zhan, X., K. S. Slobod, S. Surman, S. A. Brown, T. D. Lockey, C. Coleclough,
P. C. Doherty, and J. L. Hurwitz. 2003. Limited breadth of a T-helper cell
response to a human immunodeficiency virus envelope protein. J. Virol.
77:4231–4236.

Supplemental Materials:
Supplemental Fig. 1. T cell epitope mapping of CON6 and subtype Env immunogens. T
cell responses were determined in three mouse strains BALB/c mice (A), C57BL/6 (B)
and C3H-NeJ (C) with three overlapping Env peptide sets. T cell epitopes were first
screened with Env overlapping peptides and then confirmed with individual peptides by
performing ELISpot assays. One subtype A (92UG037), one subtype B (SF162P3) and
one subtype C (Chn19) overlapping peptide sets were used for the analysis. Positive
subtype A, B and C peptide sequences were indicated by red, blue and green colors,
respectively. Peptide sequences that were positive for stimulating the T cell response are
shown and the overlapping peptides are indicated by lines underneath the peptide
sequences. The dashed line indicates the epitopes that were missed in the polyvalent
immunogen but detected in individual subtype immunogens. The dotted line indicates the
missed epitopes that shared the identical sequences to the epitopes detected in other
immunogens. Peptide ID numbers are indicated at the end of the peptide sequences.

Supplemental Fig. 2. T cell epitope mapping of a subtype B immunogen with
heterologous subtype B peptide sets. T cell responses were determined in three mouse
strains BALB/c mice (A), C57BL/6 (B) and C3H-NeJ (C) with three overlapping Env
peptide sets (MN, 89.6 and SF162P3). T cell epitopes were first screened with Env
overlapping peptides and then confirmed with individual peptides by performing ELISpot
assays. Peptide sequences that were positive for stimulating the T cell response are shown
and the overlapping peptides are indicated by lines underneath the peptide sequences.
The dashed line indicates the epitopes that were missed in the polyvalent immunogen but
detected in individual subtype immunogens. The dotted line indicates the missed epitopes

that shared the identical sequences to the epitopes detected in other immunogens. Peptide
ID numbers are indicated at the end of the peptide sequences.
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A BALB/c

Epitope

Immunogen Peptide

B1

B2

B3

B4

B5

B6

B7

KVTFEPIPIHYCAPA (53)
STVQCTHGIRPVVST (62)
CPKVSFEPIPIHYCAPAGF (7459,7460)
VQCTHGIRPVVSTQL (7469)

UG37(A)

92RW020_A SF162(B)

B8

RIKQIINMWQRVGQA (104) LYKYKVVKIEPLGVA

B9
(120)

Chn19(C)P

JRFL_B

DTEVHNVWATHACVP(16)
DTEVHNVWATHACVP(7423)
GKEVHNVWATHACVPTDPNP(4836)

UG37(A)
SF162(B)
Chn19(C)P

KVTFEPIPIHYCAPA(53)
CPKVSFEPIPIHYCA(7459)

DTEVHNVWATHACVP(16)
DTEVHNVWATHACVP(7423)
Chn19(C)PVPVWKEAKTTLFCASDAKAYGKEVHNVWATHACVPTDPNP SSENSSEYYRLINCNTSAIT(4848)

GIVQQQSNLLRAIEAQQHLL(136,137)
VQQQNNLLRAIEAQQ(7544)
QQSNLLRAIEAQQHLLQLTV

UG37(A)

(4834)

UG37(A)
SF162(B)
Chn19(C)P

B12

(4884)

(4836)

KVTFEPIPIHYCAPA (53)
CPKVSFEPIPIHYCAPAGF(7459,7460)

DTEVHNVWATHACVP(16)
92RW020_A UG37(A)
SF162(B)
JRFL_B
VPVWKEAKTTLFCASDAKAYGKEVHNVWATHACVPTDPNP
96ZM651_C Chn19(C)P

CON6

B11

STVQCTHGIRPVVST(62)
VQCTHGIRPVVSTQL (7469) KSIPIGPGKAFYATGDIIG(7484,7485)

96ZM651_C SF162(B)

(4834)

B10

GIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQ (136,137,138,140) RVLAVERYLRDQQLL(144)
VQQQNNLLRAIEAQQ LLQLTVWGIKQLQAR (7544,7548)
QQSNLLRAIEAQQHLLQLTVWGIKQLQTRV (4884,4885)

RIKQIINMWQRVGQA(104) LYKYKVVKIEPLGVA(120)
VQCTHGIRPVVSTQL(7469)

GIVQQQSNLLRAIEAQQHL(136,137)
RVLAVERYLRDQQLL(144)
VQQQNNLLRAIEAQQ(7544)
QQSNLLRAIEAQQHLLQLTVWGIKQLQTRV(4884,4885)

(4836)

DTEVHNVWATHACVP(16)
KVTFEPIPIHYCAPA(53)
DTEVHNVWATHACVP(7423)
CPKVSFEPIPIHYCAPAGF(7459,7460)
GKEVHNVWATHACVPTDPNP SSENSSEYYRLINCNTSAIT(4848)
(4836)

LYKYKVVKIEPLGVA(120)
STVQCTHGIKPVVSTQLLLN(4854)

(136,137,138,140)

QLQARVLAVERYLRDQQLL(143,144)
GIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQ
VQQQNNLLRAIEAQQ(7544)
QQSNLLRAIEAQQHLLQLTVWGIKQLQTRV(4884,4885)

B C57BL/6
Immunogen Peptide

C1

C2

C3

C4

C5

C6

C7

92RW020_A

JRFL_B

UG37(A)
SF162(B)
Chn19(C)P

DTEVHNVWATHACVP(16)
DTEVHNVWATHACVP(7423)
GKEVHNVWATHACVPTDPNP(4836)

UG37(A)

96ZM651_C SF162(B)

DTEVHNVWATHACVP(16)
EPIPIHYCAPAGYAI(54)
DTEVHNVWATHACVP(7423)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7461)
IPIHYCTPAGYAILKCNDKT(4851)
GKEVHNVWATHACVPTDPNP(4836) SSENSSEYYRLINCNTSAIT(4848)

IIGDIRQAHCNISGE(7488)
GDIRQAHCNISKDKWNETLQ(4862)

92RW020_A UG37(A)
JRFL_B
SF162(B)
96ZM651_C Chn19(C)P

DTEVHNVWATHACVP(16)
DTEVHNVWATHACVP(7423)
GKEVHNVWATHACVPTDPNP(4836)

IIGDIRQAHCNISGE(7488)
GDIRQAHCNISKDKWNETLQ(4862)

Chn19(C)P

CON6

UG37(A)
SF162(B)
Chn19(C)P

C8

QARPKVTFEPIPIHYCAPA(52,53)
GDIIGDIRQAHCNVS(81)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7459,7460,7461) IIGDIRQAHCNISGE(7488)
SSENSSEYYRLINCNTSAIT(4848)
GDIRQAHCNISKDKWNETLQ(4862)

UG37(A)
SF162(B)
Chn19(C)P

MRVTGIRKNYQHLWRWGTMLLGML(4830, 5445)

DTEVHNVWATHACVP(16)
DTEVHNVWATHACVP(7423)
GKEVHNVWATHACVPTDPNP(4836)

QARPKVTFEPIPIHYCAPA(52,53)
CPKVSFEPIPIHYCAPAGFAILK(7459,7460,7461)

QARPKVTFEPIPIHYCAPA(52,53)
PKVSFEPIPIHYCAPAGFAILK(7459,7460,7461)

C9

Deleted

ICPTNVPWNSSWSNKSLDE(150,151)
TIKIYELIEESQIQQ(159)
CTTAVPWNASWSNKSLDQI(7558,7559)
KLICTTTVPWNTSWSNKSLD(4889)

IIGDIRQAHCNISGE(7488)
GDIRQAHCNISKDKWNETLQ(4862)

ICPTNVPWNSSWSNKSLDE(150,151)
TIKIYELIEESQIQQ(159)
CTTAVPWNASWSNKSLDQI(7558,7559)
KLICTTTVPWNTSWSNKSLD(4889)

QARPKVTFEPIPIHYCAPA(52,53)
GDIIGDIRQAHCNVSGSQW(81,82)
CNTSGLFNSTWVNGT(97)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7459,7460,7461) IIGDIRQAHCNISGE(7488)
GDIRQAHCNISKDKWNETLQ(4862)

ICPTNVPWNSSWSNKSLDE(150,151)
TIKIYELIEESQIQQ(159)
CTTAVPWNASWSNKSLDQI(7558,7559)
LLGIWGCSGKLICTTTVPWNTSWSNKSLD(4888,4889)

C C3H-NeJ
Immunogen Peptide

H1
UG37(A)

92RW020_A SF162(B)

Chn19(C)P

JRFL_B

UG37(A)
SF162(B)
Chn19(C)P
UG37(A)

96ZM651_C SF162(B)

H2

TDIISLWDQSLKPCV(27)
VLENVTENFNMWKNNMVEQ(7429,7430)
QEMVLENVTENFNMWKNDMVNQMHEDVISLWDQSLKPCVK(4838,4840)

92RW020_A UG37(A)
JRFL_B
SF162(B)
96ZM651_C Chn19(C)P

TDIISLWDQSLKPCV(27)
VLENVTENFNMWKNNMVEQ(7429,7430)
QEMVLENVTENFNMWKNDMVNQMHEDVISLWDQSLKPCVK(4838,4840)

UG37(A)
SF162(B)
Chn19(C)P

TDIISLWDQSLKPCV(27)
VLENVTENFNMWKNNMVEQ(7429,7430)
QEMVLENVTENFNMWKNDMVNQMHEDVISLWDQSLKPCVK(4838,4840)

H5

H6

QHLLKLTVWGIKQLQARVL(140,141)
NNLLRAIEAQQHLLQLTVWGIKQLQARVLAV(7545,7548,7549)
AQQHLLQLTVWGIKQLQTRVLAIERYLKDQ(4885,4886)

TDIISLWDQSLKPCV(27)
VLENVTENFNMWKNNMVEQ(7429,7430)
QEMVLENVTENFNMWKNDMVNQMHEDVISLWDQSLKPCVK(4838,4840)

H4

H7

QHLLKLTVWGIKQLQARVLAVERYLRD(140,141,143)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)
AQQHLLQLTVWGIKQLQTRVLAIERYLKDQ(4885,4886)

NQMHEDVISLWDQSLKPCVK(4840)

Chn19(C)P

CON6

H3

TDIISLWDQSLKPCV(27)

WEREIDNYTSLIYTLLEESQ(4892)

QHLLKLTVWGIKQLQARVLAVERYLRD(140,141,143)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)
AQQHLLQLTVWGIKQLQTRVLAIERYLKDQ(4885,4886)
QHLLKLTVWGIKQLQARVLAVERYLRD(140,141,143)
NNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQ(7545,7548,7549,7551)
AQQHLLQLTVWGIKQLQTRVLAIERYLKDQ(4885,4886)

SLTLTVQARQLLSGI(7540)
GAASITLTVQARQLLSGIVQ(4882)

WEREIDNYTSLIYTLLEESQ(4892)

QHLLKLTVWGIKQLQARVLAVERYLRD(140,141,143)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)
AQQHLLQLTVWGIKQLQTRVLAIERYLKDQ(4885,4886)
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A BALB/c

Epitope

Immunogen Peptide

B1

B2

JRFL_B

MN
89.6
SF162

B4

B5

B6

B7

TVQCTHGIRPVVSTQ (6271)
ACPKISFEPIPIHYC (6261)
VSFQPIPIHYCVPAGFAILK PCTNVSTVQCTHGIRPVVST (4721,4724)
CPKVSFEPIPIHYCAPAGF (7459,7460)
VQCTHGIRPVVSTQL (7469)

MN
92RW020_A 89.6
SF162
VPVWKEATTTLFCAS(6219)
GVPVWREATTTLFCASDAKAYDTEVHNVWATHACVPTDPN(4704,4706)
DTEVHNVWATHACVP(7423)

CPKVSFEPIPIHYCA(7459)

B9

ITLQCRIKQIINMWQKVGKA (4741)

TVQCTHGIRPVVSTQ(6271)
RKRIHIGPGRAFYTT(6286)
PCTNVSTVQCTHGIRPVVST(4724)
RPNNNTRRRLSIGPGRAFYARRNIIGDIRQ(4730,4731)
VQCTHGIRPVVSTQL (7469)
KSIPIGPGKAFYATGDIIG(7484,7485)
IVQQQNNLLRAIEAQ(6346)
LLLSGIVQQQNNLLRAIEAQ(4754)
VQQQNNLLRAIEAQQ(7544)

MN

96ZM651_C 89.6
SF162

YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

92RW020_A MN
89.6
JRFL_B
96ZM651_C SF162

YDTEVHNVWATHACVPTDPN(4706)

MN
89.6
SF162

DTEVHNVWATQACVP(6224)
YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

CON6

B11

IVQQQNNLLRAIEAQ (6346) LTVWGIKQLQARVLA (6351)
LLLSGIVQQQNNLLRAIEAQQNMLQLTVWGIKQLQARVLA (4754,4756)
VQQQNNLLRAIEAQQ LLQLTVWGIKQLQAR (7544,7548)

RKRIHIGPGRAFYTT(6286)
TVQCTHGIRPVVSTQ(6271)
PCTNVSTVQCTHGIRPVVST(4724) RPNNNTRRRLSIGPGRAFYARRNIIGDIRQ(4730,4731)
CPKVSFEPIPIHYCAPAGF(7459,7460)
VQCTHGIRPVVSTQL(7469)

IVQQQNNLLRAIEAQ(6346)
LLLSGIVQQQNNLLRAIEAQ(4754)
VQQQNNLLRAIEAQQ(7544)

VSFQPIPIHYCVPAGFAILK(4721)
CPKVSFEPIPIHYCAPAGF(7459,7460)

IVQQQNNLLRAIEAQ(6346)
LLLSGIVQQQNNLLRAIEAQQNMLQLTVWGIKQLQARVLA (4754,4756)
VQQQNNLLRAIEAQQ(7544)

ACPKISFEPIPIHYC(6261)

B C57BL/6
Immunogen

Peptide

C4

C2

C5

ISFEPIPIHYCAPAGFAILKCND(6262,6263,6264)
TSVITQACPKVSFQPIPIHYCVPAGFAILK(4720,4721)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7459,7460,7461)

92RW020_A

MN
89.6
SF162

JRFL_B

MN
89.6
SF162

DTEVHNVWATQACVP(6224)
YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

96ZM651_C

MN
89.6
SF162

YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

92RW020_A
JRFL_B
96ZM651_C

MN
89.6
SF162

YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

ITQACPKVSFEPIPIHYCAPAGFAILK(7459,7460,7461)

CON6

MN
89.6
SF162

DTEVHNVWATQACVP(6224)
YDTEVHNVWATHACVPTDPN(4706)
DTEVHNVWATHACVP(7423)

ISFEPIPIHYCAPAGFAILKCND(6262,6263,6264)
TSVITQACPKVSFQPIPIHY(4720)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7459,7460,7461)

ISFEPIPIHYCAPAGFAILKCND(6262,6263,6264)
VSFQPIPIHYCVPAGFAILK(4721)
CPKVSFEPIPIHYCAPAGFAILK(7459,7460,7461)
PIPIHYCAPAGFAIL(6263)
TSVITQACPKVSFQPIPIHY (4720)
ITQACPKVSFEPIPIHYCAPAGFAILK(7458,7461)
ISFEPIPIHYCAPAGFAIL(6262,6263)

C6

C7

C8

NIIGTIRQAHCNISRAKWN(6290)
RRNIIGDIRQAHCNISRAKW(4732)
IIGDIRQAHCNISGE(7488)

Deleted

NIIGTIRQAHCNISR(6290)
RRNIIGDIRQAHCNISRAKW(4732)
IIGDIRQAHCNISGE(7488)

CTTTVPWNASWSNKS(6360)
ICTTSVPWNVSWSNKSVDDI(4760)
CTTAVPWNASWSNKSLDQI(7558,7559)

NIIGTIRQAHCNISRAKWN(6290)
RRNIIGDIRQAHCNISRAKW(4732)
IIGDIRQAHCNISGE(7488)
NIIGTIRQAHCNISRAKWN(6290,6291)
RRNIIGDIRQAHCNISRAKW(4732)
IIGDIRQAHCNISGE(7488)
NIIGTIRQAHCNISR(6290)
RRNIIGDIRQAHCNISRAKW(4732)
IIGDIRQAHCNISGE(7488)

CTTTVPWNASWSNKS(6360)
ICTTSVPWNVSWSNKSVDDI(4760)
CTTAVPWNASWSNKSLDQI(7558,7559)
CTTTVPWNASWSNKS(6360)
ICTTSVPWNVSWSNKSVDDI(4760)
CTTAVPWNASWSNKSLDQI(7558,7559)

GEFFYCNTAQLFNSTWNVAG(4738)

C C3H-NeJ
Immunogen

Peptide

H1
92RW020_A

MN
89.6
SF162

JRFL_B

MN
89.6
SF162

PQEVVLGNVTENFNMWKNNM(4708)
VLENVTENFNMWKNNMVEQ(7429,7430)

96ZM651_C

MN
89.6
SF162

PQEVVLGNVTENFNMWKNNM(4708)
VLENVTENFNMWKNNMVEQ(7429,7430)

92RW020_A
JRFL_B
96ZM651_C

MN
89.6
SF162

PQEVVLGNVTENFNMWKNNM(4708)
VLENVTENFNMWKNNMVEQ(7429,7430)

CON6

MN
89.6
SF162

PQEVVLGNVTENFNMWKNNM(4708)
VLENVTENFNMWKNNMVEQ(7429,7430)

H2

H3

EDIISLWDQSLKPCV(6235)

H4

H5

H6

H7

HMLQLTVWGIKQLQARVLAVERYLKDQQLLG(6350,6351,6353,6354)
QNMLRLTVWGIKQLQARVLALERYLRDQQL(4756,4757)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)

EDIISLWDQSLKPCV(6235)

QNNLLRAIEAQQHMLQLTVWGIKQLQARVLAVERYLKDQ(6347,6350,6351,6353)

EREIDNYTSLIYSLL(6367)

QNMLRLTVWGIKQLQARVLAL (4756)
NNLLRAIEAQQHLLQLTVWGIKQLQARVLAV(7545,7548,7549)
EDIISLWDQSLKPCV(6235)

HMLQLTVWGIKQLQARVLAVERYLKDQQLLG(6350,6351,6353,6354)
QNMLRLTVWGIKQLQARVLALERYLRDQQL(4756,4757)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)
QNNLLRAIEAQQHMLQLTVWGIKQLQARVLAVERYLKDQQLLG(6347,6350,6351,6353,6354)
QNMLRLTVWGIKQLQARVLALERYLRDQQL(4756,4757)
NNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQ(7545,7548,7549,7551)

EDIISLWDQSLKPCV(6235)

EDIISLWDQSLKPCV(6235)
SLTLTVQARQLLSGI(7540)

EREIDNYTSLIYSLL(6367)

HMLQLTVWGIKQLQARVLAVERYLKDQQLLG(6350,6351,6353,6354)
QNMLRLTVWGIKQLQARVLALERYLRDQQL(4756,4757)
LLQLTVWGIKQLQARVLAVERYLKDQ(7548,7549,7551)
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Supplemental Table 1. Potential T cell epitopes identified in three mouse strains
BALB/c

C57BL/6

epitope

sequences

epitope

B1

GVPVWKEAKTTLFCASDAKA

C1

B2

GKTEVHNVWATHACVPTDPNP

B3

sequences

C3H
epitope

sequences

MRVTGIRKNYQHLWRWGTMLLGML

H1

QEMVLENVTENFNMWKNPM

C2

GKEVHNVWATHACVPTDPNP

H2

VNQMHEDVISLWDQSLKPCV

SSENSSEYYRLINCNTSAIT

C3

SSENSSEYYRLINCNTSA

H3

GAASITLTVQARQLLSGIVQ

B4

CPKVSFEPIPIHYCAPAGF

C4

ITQACPKVSFEPIPIHYC

H4

NNLLRAIEAQ

B5

STVQCTHGIRPVVSTQLLLN

C5

TPAGYAILKCNDKT

H5

QRLLQLTVWGIKQLQ

B6

KSIPIGPGKAFYATGDIIG

C6

GDIIGDIRQAHCNISKDKWNETLQ

H6

ARVLAVERYLKDQ

B7

RIKQIINMWQRVGQA

C7

CNTSGLFNSTWVNGT

H7

WEREIDNYTSLIYTLLEESQ

B8

LYKYKVVKIEPLGVA

C8

LLGIWGCSGKLICTTTVPWNTSWSNKSL

B9

GIVQQQSNLLRAI

C9

TIKIYELIEESQIQQ

B10

EAQQHLLQL

B11

TVWGIKQLQARV

B12

RVLAVERYLRDQQLL
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